The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Cutaneous melanoma: From pathogenesis to therapy (Review)
Open accessAbstract
In less than 10 years, melanoma treatment has been revolutionized with the approval of tyrosine kinase inhibitors and immune checkpoint inhibitors, which have been shown to have a significant impact on the prognosis of patients with melanoma. The early steps of this transformation have taken place in research laboratories. The mitogen‑activated protein kinase (MAPK) pathway, phosphoinositol‑3‑kinase (PI3K) pathway promote the development of melanoma through numerous genomic alterations on different components of these pathways. Moreover, melanoma cells deeply interact with the tumor microenvironment and the immune system. This knowledge has led to the identification of novel therapeutic targets and treatment strategies. In this review, the epidemiological features of cutaneous melanoma along with the biological mechanisms involved in its development and progression are summarized. The current state‑of‑the‑art of advanced stage melanoma treatment strategies and the currently available evidence of the use of predictive and prognostic biomarkers are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Genomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Distinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Weber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
A landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610 · cited 4×
“…[phosphatase and tensin homolog ( PTEN ) and KIT proto-oncogene receptor tyrosine kinase ( KIT )], resistance to apoptosis [tumor protein p53 ( TP53 )], cell cycle control [cyclin-dependent kinase inhibitor 2A ( CDKN2A )] and replicative lifespan [telomerase reverse transcriptase ( TERT )] (47,48).”
InfluentialPI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,572
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
Differential regulation and properties of MAPKs
Raman, M., Chen, W., & Cobb, M. H. (2007) · Oncogene · doi:10.1038/sj.onc.1210392 · Cited by 1,430 · cited 1×
“The MAPK pathway is physiologically involved in the transduction of extracellular signals, such as growth factors and hormones, to the nucleus, leading to the expression of genes that are central drivers of cell proliferation, differentiation and survival (50,51).”
Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J.-J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60898-4 · Cited by 1,399
Melanocyte biology and skin pigmentation
Lin, J. Y., & Fisher, D. E. (2007) · Nature · doi:10.1038/nature05660 · Cited by 1,379 · cited 1×
“The melanin pigment ultimately operates as a shield for UV radiation, thus preventing further DNA alteration (30).”
Melanoma biology and new targeted therapy
Gray-Schopfer, V., Wellbrock, C., & Marais, R. (2007) · Nature · doi:10.1038/nature05661 · Cited by 1,371
Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure
Gandini, S., Sera, F., Cattaruzza, M. S., Pasquini, P., Picconi, O., Boyle, P., & Melchi, C. F. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2004.10.016 · Cited by 1,266
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Luke, J. J., Flaherty, K. T., Ribas, A., & Long, G. V. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.43 · Cited by 1,254
The RAF proteins take centre stage
Wellbrock, C., Karasarides, M., & Marais, R. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1498 · Cited by 1,228
Schachter, J., Ribas, A., Long, G. V., Arance, A., Grob, J.-J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31601-x · Cited by 1,225
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
Krauthammer, M., Kong, Y., Ha, B. H., Evans, P., Bacchiocchi, A., McCusker, J. P., Cheng, E., Davis, M. J., Goh, G., Choi, M., et al. (2012) · Nature Genetics · doi:10.1038/ng.2359 · Cited by 1,191
The Genetic Evolution of Melanoma from Precursor Lesions
Shain, A. H., Yeh, I., Kovalyshyn, I., Sriharan, A., Talevich, E., Gagnon, A., Dummer, R., North, J., Pincus, L., Ruben, B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502583 · Cited by 1,065
Ascierto, P. A., McArthur, G. A., Dréno, B., Atkinson, V., Liszkay, G., Di Giacomo, A. M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30122-x · Cited by 1,022
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R. C., Moriceau, G., Chodon, T., Guo, R., Johnson, D. B., Dahlman, K. B., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0642 · Cited by 982
McArthur, G. A., Chapman, P. B., Robert, C., Larkin, J., Haanen, J. B., Dummer, R., Ribas, A., Hogg, D., Hamid, O., Ascierto, P. A., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70012-9 · Cited by 977
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Van Allen, E. M., Wagle, N., Sucker, A., Treacy, D. J., Johannessen, C. M., Goetz, E. M., Place, C. S., Taylor-Weiner, A., Whittaker, S., Kryukov, G. V., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0617 · Cited by 912
Shain, A. H., & Bastian, B. C. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.37 · Cited by 896
The pathogenesis of melanoma induced by ultraviolet radiation
Gilchrest, B. A., Eller, M. S., Geller, A. C., & Yaar, M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401707 · Cited by 876
Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi
Gandini, S., Sera, F., Cattaruzza, M. S., Pasquini, P., Abeni, D., Boyle, P., & Melchi, C. F. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2004.10.015 · Cited by 842
Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
Zuo, L., Weger, J., Yang, Q., Goldstein, A. M., Tucker, M. A., Walker, G. J., Hayward, N., & Dracopoli, N. C. (1996) · Nature Genetics · doi:10.1038/ng0196-97 · Cited by 818 · cited 1×
“Germline mutations in cyclin-dependent kinase inhibitor 2A ( CDKN2A or p16) and, less common, mutations in cyclin-dependent kinase 4 ( CDK4 ) are the most frequent genetic abnormalities identified in these families (26-28).”
Melanoma and sun exposure: An overview of published studies
Elwood, J. M., & Jopson, J. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19971009)73:2<198::aid-ijc6>3.0.co;2-r · Cited by 791
Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification.
Rastrelli, M., Tropea, S., Rossi, C. R., & Alaibac, M. (2014) · PubMed · Cited by 708
NRAS mutation status is an independent prognostic factor in metastatic melanoma
Jakob, J. A., Bassett, R. L., Ng, C. S., Curry, J. L., Joseph, R. W., Alvarado, G. C., Rohlfs, M. L., Richard, J., Gershenwald, J. E., Kim, K. B., et al. (2012) · Cancer · doi:10.1002/cncr.26724 · Cited by 689
KIT Gene Mutations and Copy Number in Melanoma Subtypes
Beadling, C., Jacobson-Dunlop, E., Hodi, F. S., Le, C., Warrick, A., Patterson, J., Town, A., Harlow, A., Cruz, F., Azar, S., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0575 · Cited by 646
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
Hugo, W., Shi, H., Sun, L., Piva, M., Song, C., Kong, X., Moriceau, G., Hong, A., Dahlman, K. B., Johnson, D. B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.061 · Cited by 600
Anatomy, histology and immunohistochemistry of normal human skin.
Kanitakis, J. (2002) · PubMed · Cited by 592
The International Agency for Research on Cancer Working Group on artificial ultraviolet (UV) light and skin cancer (2007) · International Journal of Cancer · doi:10.1002/ijc.22453 · Cited by 561
Steelman, L. S., Chappell, W. H., Abrams, S. L., Kempf, C. R., Long, J., Laidler, P., Mijatovic, S., Maksimovic-Ivanic, D., Stivala, F., Mazzarino, M. C., et al. (2011) · Aging · doi:10.18632/aging.100296 · Cited by 553
Self-citationThe Molecular Pathology of Melanoma: An Integrated Taxonomy of Melanocytic Neoplasia
Bastian, B. C. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104658 · Cited by 513
Chappell, W. H., Steelman, L. S., Long, J. M., Kempf, R. C., Abrams, S. L., Franklin, R. A., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.240 · Cited by 510
Self-citationPTEN signaling pathways in melanoma
Wu, H., Goel, V., & Haluska, F. G. (2003) · Oncogene · doi:10.1038/sj.onc.1206451 · Cited by 480
Genetic Interaction Between NRAS and BRAF Mutations and PTEN/MMAC1 Inactivation in Melanoma
Tsao, H., Yang, G., Goel, V., Wu, H., & Haluska, F. G. (2004) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2004.22243.x · Cited by 467
Farmer, E. R., Gonin, R., & Hanna, M. P. (1996) · Human Pathology · doi:10.1016/s0046-8177(96)90157-4 · Cited by 440
Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas
Krauthammer, M., Kong, Y., Bacchiocchi, A., Evans, P., Pornputtapong, N., Wu, C., McCusker, J. P., Ma, S., Cheng, E., Straub, R., et al. (2015) · Nature Genetics · doi:10.1038/ng.3361 · Cited by 402
A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
Whittaker, S. R., Theurillat, J.-P., Van Allen, E., Wagle, N., Hsiao, J., Cowley, G. S., Schadendorf, D., Root, D. E., & Garraway, L. A. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0470 · Cited by 359
Indoor Tanning and Risk of Melanoma: A Case-Control Study in a Highly Exposed Population
Lazovich, D., Vogel, R. I., Berwick, M., Weinstock, M. A., Anderson, K. E., & Warshaw, E. M. (2010) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-1249 · Cited by 353 · cited 3×
“NRAS is mutated in 15-30% of melanomas and in the majority of cases, these mutations are missense mutations of codon 12, 13 or 61 (the latter account for 80% of all NRAS mutations in melanoma) (31,62).”
β-Catenin Signaling Controls Metastasis in Braf-Activated Pten-Deficient Melanomas
Damsky, W. E., Curley, D. P., Santhanakrishnan, M., Rosenbaum, L. E., Platt, J. T., Gould Rothberg, B. E., Taketo, M. M., Dankort, D., Rimm, D. L., McMahon, M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.030 · Cited by 351
Gray, E. S., Rizos, H., Reid, A. L., Boyd, S. C., Pereira, M. R., Lo, J., Tembe, V., Freeman, J., Lee, J. H. J., Scolyer, R. A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5788 · Cited by 336
Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
Nissan, M. H., Pratilas, C. A., Jones, A. M., Ramirez, R., Won, H., Liu, C., Tiwari, S., Kong, L., Hanrahan, A. J., Yao, Z., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2625 · Cited by 319
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Franklin, R. A., Montalto, G., Cervello, M., Libra, M., Candido, S., Malaponte, G., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.659 · Cited by 314
Self-citationArchier, E., Devaux, S., Castela, E., Gallini, A., Aubin, F., Le Maître, M., Aractingi, S., Bachelez, H., Cribier, B., Joly, P., et al. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04520.x · Cited by 311
Loss of PTEN promotes tumor development in malignant melanoma.
Stahl, J. M., Cheung, M., Sharma, A. K., Trivedi, N. R., Shanmugam, S., & Robertson, G. P. (2003) · PubMed · Cited by 310
Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds
Gruis, N. A., van der Velden, P. A., Sandkuijl, L. A., Prins, D. E., Weaver-Feldhaus, J., Kamb, A., Bergman, W., & Frants, R. R. (1995) · Nature Genetics · doi:10.1038/ng0795-351 · Cited by 310
Oncogenic Ras in tumour progression and metastasis
Giehl, K. (2005) · Biological Chemistry · doi:10.1515/bc.2005.025 · Cited by 287
Rimm, D. L., Caca, K., Hu, G., Harrison, F. B., & Fearon, E. R. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65278-9 · Cited by 283
Epigenetic Silencing of the PTEN Gene in Melanoma
Mirmohammadsadegh, A., Marini, A., Nambiar, S., Hassan, M., Tannapfel, A., Ruzicka, T., & Hengge, U. R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0384 · Cited by 279
Melanoma epidemiology, biology and prognosis
Ali, Z., Yousaf, N., & Larkin, J. (2013) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2013.07.012 · Cited by 278
Mitogen-actived protein kinase activation is an early event in melanoma progression.
Cohen, C., Zavala-Pompa, Á., Sequeira, J., Shoji, M., Sexton, D. G., Cotsonis, G., Cerimele, F., Govindarajan, B., Macaron, N. C., & Arbiser, J. L. (2002) · PubMed · Cited by 275
The INK4a/ARF locus and melanoma
Sharpless, N. E., & Chin, L. (2003) · Oncogene · doi:10.1038/sj.onc.1206461 · Cited by 261
International Prevalence of Indoor Tanning: A Systematic Review and Meta-analysis
Wehner, M. R., Chren, M.-M., Nameth, D., Choudhry, A., Gaskins, M., Nead, K. T., Boscardin, W. J., & Linos, E. (2014) · JAMA Dermatology · doi:10.1001/jamadermatol.2013.6896 · Cited by 260
Elucidating Distinct Roles for NF1 in Melanomagenesis
Maertens, O., Johnson, B., Hollstein, P., Frederick, D. T., Cooper, Z. A., Messiaen, L., Bronson, R. T., McMahon, M., Granter, S., Flaherty, K., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0313 · Cited by 258
Rubinstein, J. C., Sznol, M., Pavlick, A. C., Ariyan, S., Cheng, E., Bacchiocchi, A., Kluger, H. M., Narayan, D., & Halaban, R. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-67 · Cited by 254
Ageing: from inflammation to cancer
Leonardi, G. C., Accardi, G., Monastero, R., Nicoletti, F., & Libra, M. (2018) · Immunity & Ageing · doi:10.1186/s12979-017-0112-5 · Cited by 241 · cited 1×
“An interesting finding is that BRAF is mutated in up to 80% of benign nevi, resulting in limited melanocyte proliferation through the oncogene-mediated activation of cell senescence (34,35).”
Self-citationThe Role of the PI3K-AKT Pathway in Melanoma
Davies, M. A. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31824d448c · Cited by 240
Girotti, M. R., Gremel, G., Lee, R., Galvani, E., Rothwell, D., Viros, A., Mandal, A. K., Lim, K. H. J., Saturno, G., Furney, S. J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1336 · Cited by 231
Hereditary melanoma: Update on syndromes and management
Soura, E., Eliades, P. J., Shannon, K., Stratigos, A. J., & Tsao, H. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.08.038 · Cited by 230
Larkin, J., Lao, C. D., Urba, W. J., McDermott, D. F., Horak, C., Jiang, J., & Wolchok, J. D. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1184 · Cited by 223
Bauer, J., & Garbe, C. (2003) · Pigment Cell Research · doi:10.1034/j.1600-0749.2003.00047.x · Cited by 209
Lovly, C. M., Dahlman, K. B., Fohn, L. E., Su, Z., Dias-Santagata, D., Hicks, D. J., Hucks, D., Berry, E., Terry, C., Duke, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035309 · Cited by 206
Santiago-Walker, A., Gagnon, R., Mazumdar, J., Casey, M., Long, G. V., Schadendorf, D., Flaherty, K., Kefford, R., Hauschild, A., Hwu, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0321 · Cited by 206
Wang, Y. F., Jiang, C. C., Kiejda, K. A., Gillespie, S., Zhang, X. D., & Hersey, P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0665 · Cited by 194
Zimmer, L., Apuri, S., Eroglu, Z., Kottschade, L. A., Forschner, A., Gutzmer, R., Schlaak, M., Heinzerling, L., Krackhardt, A. M., Loquai, C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.009 · Cited by 190
Genetic Epidemiology of Cutaneous Melanoma: A Global Perspective
Goldstein, A. M., & Tucker, M. A. (2001) · Archives of Dermatology · doi:10.1001/archderm.137.11.1493 · Cited by 183
CDKN2A/p16 is inactivated in most melanoma cell lines.
Castellano, M., Pollock, P. M., Walters, M. K., Sparrow, L. E., Down, L. M., Gabrielli, B. G., Parsons, P. G., & Hayward, N. K. (1997) · PubMed · Cited by 171
McCubrey, J. A., Steelman, L. S., Kempf, C. R., Chappell, W. H., Abrams, S. L., Stivala, F., Malaponte, G., Nicoletti, F., Libra, M., Bäsecke, J., et al. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22647 · Cited by 171
Self-citationNRAS mutant melanoma: biological behavior and future strategies for therapeutic management
Fedorenko, I. V., Gibney, G. T., & Smalley, K. S. M. (2013) · Oncogene · doi:10.1038/onc.2012.453 · Cited by 167
Melanoma: Molecular pathogenesis and emerging target therapies (Review)
Libra, M. (2009) · International Journal of Oncology · doi:10.3892/ijo_00000277 · Cited by 163
Self-citationCase-Control Study of Malignant Melanoma in Washington State
White, E., Kirkpatrick, C. S., & Lee, J. A. H. (1994) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a117092 · Cited by 152
Lactobacillus rhamnosus GG: An Overview to Explore the Rationale of Its Use in Cancer
Banna, G. L., Torino, F., Marletta, F., Santagati, M., Salemi, R., Cannarozzo, E., Falzone, L., Ferraù, F., & Libra, M. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00603 · Cited by 150
Self-citationOccupational exposure to carcinogens: Benzene, pesticides and fibers
Falzone, L., Marconi, A., Loreto, C., Franco, S., Spandidos, D. A., & Libra, M. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5791 · Cited by 138
Self-citationHandolias, D., Salemi, R., Murray, W. K., Tan, A., Liu, W. J., Virós, A., Dobrovic, A., Kelly, J. W., & McArthur, G. A. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00671.x · Cited by 137
Self-citationRambow, F., Job, B., Petit, V., Gesbert, F., Delmas, V., Seberg, H., Meurice, G., Otterloo, E. V., Dessen, P., Robert, C., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.037 · Cited by 129
Sandri, S., Faião‐Flores, F., Tiago, M., Pennacchi, P. C., Massaro, R. R., Alves-Fernandes, D. K., Berardinelli, G. N., Evangelista, A. F., Vazquez, V. D. L., Reis, R. M., et al. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.017 · Cited by 115
Melanocortin 1 receptor variants: Functional role and pigmentary associations
Dessinioti, C., Antoniou, C., Katsambas, A., & Stratigos, A. J. (2011) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2011.00970.x · Cited by 111 · cited 1×
“Individuals with characteristics, such as red hair, a light complexion and light eyes exhibit a low pigmentation, with a consequent heightened sensitivity to UV exposure (24).”
Metalloproteinases in melanoma
Moro, N., Mauch, C., & Zigrino, P. (2014) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2014.01.002 · Cited by 110
Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis
Nogueira, C., Kim, K.-H., Sung, H., Paraiso, K. H. T., Dannenberg, J.-H., Bosenberg, M., Chin, L., & Kim, M. (2010) · Oncogene · doi:10.1038/onc.2010.349 · Cited by 108
Nelemans, P. J., Groenendal, H., Kiemeney, L. A. L. M., Rampen, F. H. J., Ruiter, D. J., & Verbeek, A. L. M. (1993) · Environmental Health Perspectives · doi:10.1289/ehp.93101252 · Cited by 103
NF-κB inhibition is associated with OPN/MMP-9 downregulation in cutaneous melanoma
Guarneri, C., Bevelacqua, V., Polesel, J., Falzone, L., Cannavó, P. S., Spandidos, D. A., Malaponte, G., & Libra, M. (2017) · Oncology Reports · doi:10.3892/or.2017.5362 · Cited by 97
Self-citationMMP-9 overexpression is associated with intragenic hypermethylation of MMP9 gene in melanoma
Falzone, L., Salemi, R., Travali, S., Scalisi, A., McCubrey, J. A., Candido, S., & Libra, M. (2016) · Aging · doi:10.18632/aging.100951 · Cited by 90
Self-citationNevus density and melanoma risk in women: A pooled analysis to test the divergent pathway hypothesis
Olsen, C. M., Zens, M. S., Stukel, T. A., Sacerdote, C., Chang, Y., Armstrong, B. K., Bataille, V. A., Berwick, M., Elwood, M., Holly, E. A., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.24011 · Cited by 87
Simeone, E., & Ascierto, P. A. (2012) · Journal of Immunotoxicology · doi:10.3109/1547691x.2012.678021 · Cited by 84
Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma
Carlino, M. S., Long, G. V., Kefford, R. F., & Rizos, H. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.021 · Cited by 75
Pennello, G. A., Devesa, S. S., & Gail, M. H. (2000) · PubMed · Cited by 71
Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer
Pappalardo, F., Russo, G. L., Candido, S., Pennisi, M. A., Cavalieri, S., Motta, S., McCubrey, J. A., Nicoletti, F., & Libra, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152104 · Cited by 66
Self-citationLee, K. R., Lee, J. S., Kim, Y. R., SONG, I. G., & Hong, E. K. (2014) · Oncology Reports · doi:10.3892/or.2014.3103 · Cited by 61
Genetic predisposition to melanoma
Hawkes, J. E., Truong, A., & Meyer, L. J. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.08.003 · Cited by 61
Analysis of the B-RAFV600E mutation in cutaneous melanoma patients with occupational sun exposure
Candido, S., Rapisarda, V., Marconi, A., Malaponte, G., Bevelacqua, V., Gangemi, P., Scalisi, A., McCubrey, J. A., Maestro, R., Spandidos, D. A., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.2977 · Cited by 60
Self-citationRichtig, G., Höeller, C., Kashofer, K., Aigelsreiter, A. M., Heinemann, A., Kwong, L. N., Pichler, M., & Richtig, E. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15436 · Cited by 60
Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy
Speeckaert, R., van Geel, N., Vermaelen, K., Lambert, J., Gele, M. V., Speeckaert, M. M., & Brochez, L. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00799.x · Cited by 57
Antibody therapies for melanoma: New and emerging opportunities to activate immunity (Review)
Malas, S., Harrasser, M., Lacy, K. E., & Karagiannis, S. N. (2014) · Oncology Reports · doi:10.3892/or.2014.3275 · Cited by 50
Donia, M., Harbst, K., van Buuren, M., Kvistborg, P., Lindberg, M. F., Andersen, R. S., Idorn, M., Ahmad, S. M., Ellebæk, E., Mueller, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3172 · Cited by 48
Self-citationGibney, G. T., & Smalley, K. S. M. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0017 · Cited by 47
Dysplastic nevi and other risk markers for melanoma.
Seykora, J. T., & Elder, D. (1996) · PubMed · Cited by 40
Mangana, J., Cheng, P. F., Schindler, K., Weide, B., Held, U., Frauchiger, A. L., Romano, E., Kähler, K. C., Rozati, S., Rechsteiner, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139438 · Cited by 31
Akiyama, Y., Nonomura, C., Kondou, R., Miyata, H., Ashizawa, T., Maeda, C., Mitsuya, K., Hayashi, N., Nakasu, Y., & Yamaguchi, K. D. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3586 · Cited by 22
Computational modeling in melanoma for novel drug discovery
Pennisi, M. A., Russo, G. L., Salvatore, V. D., Candido, S., Libra, M., & Pappalardo, F. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1174688 · Cited by 19
Self-citation
Cited by
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
Falzone, L., Salomone, S., & Libra, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01300 · Cited by 908
Self-citationRole of PI3K/AKT pathway in cancer: the framework of malignant behavior
Jiang, N., Dai, Q., Su, X., Fu, J., Feng, X., & Peng, J. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05435-1 · Cited by 571
Drug repositioning: Progress and challenges in drug discovery for various diseases
Hua, Y., Dai, X., Xu, Y., Xing, G., Liu, H., Lu, T., Chen, Y., & Zhang, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114239 · Cited by 232
Clinical protein science in translational medicine targeting malignant melanoma
Gil, J., Betancourt, L. H., Pla, I., Sanchez, A., Appelqvist, R., Miliotis, T., Kuras, M., Oskolas, H., Kim, Y., Horvath, Z., et al. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09468-6 · Cited by 45
Differentiation States of Phenotypic Transition of Melanoma Cells Are Revealed by 3D Cell Cultures
Fontana, F., Sommariva, M., Anselmi, M., Bianchi, F., Limonta, P., & Gagliano, N. (2024) · Cells · doi:10.3390/cells13020181 · Cited by 11
Metadata
- Authors
- Leonardi, G., Falzone, L., Salemi, R., Zangh�, A., Spandidos, D., Mccubrey, J., Candido, S., & Libra, M.
- Venue
- International Journal of Oncology
- Publisher
- Spandidos Publications
- Published
- 2018-02-27
- Volume
- 52
- Issue
- 4
- Pages
- 1071-1080
- ISSN
- 1019-6439 (ISSN-L)
- 1791-2423
- OpenAlex
- W2791962996
- Cited by
- 588
- References
- 121
- FWCI
- 18.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.